1 Jul 2019 07:00
4D PHARMA PLC
("4D", the "Company" or, together with its subsidiaries, the "Group")
Appointment of N+1 Singer as Nominated Adviser & Joint Broker
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, is pleased to announce the appointment of N+1 Singer as Nominated Adviser and Joint Broker with immediate effect. Bryan Garnier & Co. Limited will remain as Joint Broker.
End
Enquiries
4D pharma plc Duncan Peyton, Chief Executive Officer Fay Weston, Head of Investor Relations |
+ 44 (0)113 895 0130 + 44 (0)7990 381713
|
N+1 Singer (Nominated Adviser & Joint Broker) Aubrey Powell, Justin McKeegan, Alex Bond (Corporate Finance) Tom Salvesen (Corporate Broking)
| +44 (0) 20 7496 3000
|
Bryan Garnier & Co. Limited - Joint Broker Dominic Wilson / Phil Walker
| +44 (0)20 7332 2500 |
About 4D
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has three clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease.